Illumina® MiSeq Next Generation Sequencer for Transfusion Medicine

The National Institutes of Health (NIH) intends to award a fixed priced purchase order on a sole source basis to  Illumina, Inc.,  5200 Illumina Way, San Diego, CA  92122-4616 to procure the Illumina® MiSeq Next Generation Sequencer.  This instrument will be used by the NIH,  Human Leukocyte Antigen (HLA) Lab  to produce high resolution HLA typing results for the numerous transplant protocols supported by the laboratory.  It will replace the Illumina® MiSeq system that was purchased in 2015.

Illumina is the sole manufacturer and distributor of this instrument. The Illumina® MiSeq system is an integrated instrument that performs clonal amplification, genomic DNA sequencing, and data analysis with base calling, alignment, variant calling, and reporting in a single run.  The Illumina® MiSeq system will provide the Lab with the highest HLA typing results possible. The transplant protocols served by the HLA Lab require highest resolution possible to increase the chance of a successful transplant.  The HLA Lab requires this specific instrument because it currently has two existing Illumina® MiSeq instruments in the lab and a compatible instrument is needed to integrate with the existing procedures and quality control assessments made for this instrument.

This acquisition is being conducted under the authority of the FAR Subpart 13.106-1(b)(i), Contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available. Interested concerns capable of providing the same or similar products or services as described in this notice may submit a capability statement outlining their capabilities. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. The total dollar value of this purchase order shall not exceed the SAT at $250,000.00.

Each response should include the following Business Information:
a. DUNS.
b. Company Name, address, POC, Phone and Email address
c. Current GSA Schedules or NAICS codes appropriate to this Award.
d. Type of Company (i.e., small business, 8(a), woman owned, hubZone, veteran owned, etc.) as validated in System For Award Management (SAM). All offerors must register on the SAM located at http://www.sam.gov/portal/SAM/#1
e. Capability Statement

Comments to this announcement may be submitted to the Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Malinda Dehner, Contract Specialist, dehnerm@cc.nih.gov by the due date and time marked in this notice